Crohn's Disease: The Complete Guide to Medical Management

Gary R. Lichtenstein, MD, FACP, FACG, AGAF

Chapter 18: Anti-TNFα Therapy from Symptoms to Molecules: Impact of Individual Variability on Anti-TNFα Optimization Strategies (continued)

Ellen J. Scherl, MD, FACP, AGAF

—Sir William Osler, 1892 The greatest challenge for physicians treating Crohn’s disease today is to move from generalized symptom-oriented step-up strategies to individualized prevention-oriented—early intervention/top-down—strategies involving personalized and proactive targeting of molecules. The recent advent of molecular-targeted therapies such as anti-tumor necrosis factor (anti-TNFα) agents has the potential to change the immunobiology of inflammation, clinical outcomes, and natural history of Crohn’s disease in select patients. Whether biologic…